5 completed, 1 unknown. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Human Papillomavirus: new trials by email Literature Review of Human Papillomavirus trials Research Report on Human Papillomavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya Artesunate vaginal inserts, Placebo vaginal inserts - Human Immunodeficiency Virus, Human Papillomavirus | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 120 | 2025-01-22 | 2026-05-14 |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females HPV-16/18 vaccine - Human Papillomavirus, Cervical Intraepithelial Neoplasia | Phase 2 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 900 | 2016-02-01 | 2023-04-13 |
| Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL TVGV-1, GPI-0100, Placebo - Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Unknown | THEVAX Genetics Vaccine | 10 | 2015-11-01 | 2017-10-25 |
| Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females HPV vaccine, Placebo - Human Papillomavirus | Phase 2 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 1200 | 2013-09-01 | 2023-04-13 |
| Study of Gardasil in Mid-Adult Males (MAM) Gardasil - Human Papillomavirus | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 150 | 2013-02-19 | 2021-09-16 |
Uterine Cervical Dysplasia (3) · Uterine Cervical Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Anus Neoplasms (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Oropharyngeal Neoplasms (1) · Penile Neoplasms (1) · Persistent Infection (1) · Squamous Intraepithelial Lesions (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Neoplasms (5) · Urogenital Diseases (5) · Uterine Cervical Diseases (5) · Uterine Diseases (5) · Precancerous Conditions (3) · Genital Neoplasms, Female (2) · Infections (2) · Neoplasms by Site (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Neoplasms (2) · Uterine Neoplasms (2)
Papillomavirus Vaccines (2) · Adjuvants, Pharmaceutic (1) · Antigens (1) · GPI0100 (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · bintrafusp alfa protein, human (1) · entinostat (1)
Shanghai Zerun Biotechnology Co.,Ltd (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · National Cancer Institute (NCI) (1) · THEVAX Genetics Vaccine (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (3) · China (2) · Kenya (1) · Mexico (1)
Anna Giuliano, Ph.D. (1) · Chemtai Mungo, MD, MPH (1) · Frank L Douglas, PhD, MD (1) · Hoyoung M Maeng, M.D. (1) · Rong-cheng Li, MD (1) · Zhaojun Mo (1)
R34CA284983 (1)